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Summary 
Adherence to Clostridium difficile infection treatment guidelines is associated with lower 
recurrence rates and mortality as well as cost savings. Our survey of Irish clinicians indicates 
that patients are managed using a variety of approaches. FMT is potentially underutilised 
despite its recommendation in national and European guidelines. 
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TEXT  
Introduction 
C. difficile infection (CDI) is characterised by reductions in microbial diversity of the 
complex gut microbiota, and stool transplantation from healthy donors (faecal microbiota 
transplantation, FMT) is increasingly recommended for treatment of patients with recurrent 
CDI.1, 2 
CDI is a mandatory notifiable infection under Irish public health legislation.  In 2014, 
155/1613 (8.5%) of cases were classified as recurrent CDI (i.e. CDI that occurs within 8 
weeks following the onset of a previous episode),2 though sub-classification on the number of 
recurrences is not reported.3  Irish guidelines recommend metronidazole, vancomycin or 
fidaxomicin (following infection specialist consultation) for the first non-severe CDI episode 
and the first non-severe recurrence, with  FMT recommended as an option for second and 
subsequent recurrences.2 Given the quality of evidence available, this is given a Grade A 
recommendation. However, FMT is likely underutilised, possibly due to logistical 
difficulties, regulations, or perceived patient aversion.4 
We performed a national survey to assess CDI management practices to inform the national 
CDI guideline implementation process. 
Methods 
In September 2015 a ten question survey was developed principally based on a previous 
United Kingdom survey and following a literature review.7 The aim was to design a short 
questionnaire that would take no longer than three minutes to complete, targeting senior 
decision makers. Questions regarding current management of CDI, experience with and 
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beliefs about FMT were included. The full questionnaire is available as a supplementary file. 
The survey was formulated using an online survey tool (www.surveymonkey.com) and 
circulated via the relevant professional societies to Irish hospital consultants in specialties 
most likely to regularly manage CDI (Irish Society of Clinical Microbiologists, Irish Society 
of Gastroenterology, Infectious Disease Society of Ireland, Irish Society of Physicians in 
Geriatric Medicine, Irish Association of Coloproctology). Responses were accepted up until 
the close of the survey in February 2016. 
Results 
Ninety-four surveys were completed by gastroenterologists (n=42), microbiologists (n=26), 
infectious diseases physicians (n=10), geriatricians (n=8) and general/colorectal surgeons 
(n=8).   
CDI treatment options selected by respondents are summarised in Table I.  Oral 
metronidazole was most commonly selected for the first episode of non-severe CDI.  
Vancomycin was most frequently recommended for the first and second non-severe 
recurrence.  Both FMT and fidaxomicin were more frequently recommended for the third or 
subsequent recurrence than for earlier recurrences.  
Fidaxomicin was most frequently recommended by an infection specialist (i.e. a 
microbiologist or infectious diseases consultant), particularly for earlier episodes (i.e. first 
episode and first recurrence). 
Fourteen respondents (14.9%) reported previous FMT use, mostly in the previous year 
(10/14).  One respondent, a microbiologist, reported recommending FMT on more than 10 
occasions. In contrast to its low usage, the majority had seen potential FMT candidates in the 
past year, principally patients with recurrent CDI and, in some instances, severe CDI. (Table 
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1) Twenty-eight had not seen any patients in the previous year who they considered suitable 
FMT candidates. 
Factors which influenced respondents to recommend FMT included: the availability of 
prepared stool (64/94; 68.1%), donor selection logistics (50/94; 53.2%), availability of a 
national agreed protocol (46/94; 48.9%) and patient acceptability (45/94; 47.9%). Patient 
safety concerns, overall cost of the procedure and antimicrobial resistance as a result of the 
procedure were less likely to influence decision making (9/94 (9.6%), 7/94 (7.4%), 4/94 
(4.3%), respectively).  
Enablers that would facilitate respondents either recommending or performing FMT 
included: availability of donor stool (76/94; 80.9%) and a national agreed protocol (69/94; 
73.4%), patient information resources (43/94, 45.7%), laboratory resources / logistics (39/94, 
41.5%) and endoscopy resources / logistics (35 /94, 37.2%). 
Discussion  
Adherence to CDI treatment guidelines is associated with lower recurrence rates and 
mortality as well as cost savings.5, 6 Irish CDI patients are managed using a variety of 
approaches.  National guidelines recommend metronidazole for the first episode or first 
recurrence of non-severe CDI, with fidaxomicin or vancomycin as alternatives.2   It is notable 
that vancomycin is more commonly recommended for the first CDI recurrence, versus 
metronidazole for the first episode.  The frequent recommendation of probiotics (by a quarter 
of respondents) despite insufficient evidence to support their use was a significant variation 
from guidelines.2 Multiple reasons for these variations in prescribing may exist, such as local 
policy and personal preference.  These reasons were not examined here and, given the small 
numbers in each specialty group, analysis of prescribing practices between specialties was 
not performed. This discordance is not unique to Ireland, with other studies reporting similar 
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findings.5, 6 Few studies explore prescribers’ rationale for these discordances, though lack of 
guideline awareness may be a major factor.6 
This survey highlights the desire by Irish clinicians to use FMT in CDI management.  It also 
indicates that FMT is potentially underutilised despite its national and European 
recommendations.1, 2 Similar findings have been reported elsewhere.4, 7 A United Kingdom 
survey reported that 94% of hospital specialists had seen at least one patient for whom they 
would recommend FMT; however only 22% reported using FMT in the last 10 years.  Similar 
to our findings, the availability of regional guidelines and pre-screened stool were factors 
considered to facilitate FMT. 7   
Logistical issues, specifically availability of prepared screened stool, donor selection 
logistics, and availability of a national agreed protocol, were the most likely factors to be 
taken into account when consideration was given to recommending FMT.  It follows, 
therefore, that the ready availability of donor stool was considered the main factor to 
facilitate wider use of FMT. Issues such as patient safety concerns and antimicrobial 
resistance were of less concern, suggesting that respondents believe that FMT is a safe 
procedure.  Using a directed donor model (i.e. where an individual is identified as a stool 
donor, followed by local donor / sample screening for potentially transmissible conditions) 
can be time consuming, expensive and needs to be well-regulated to minimise any potential 
risk to the patient.8  This approach could result in patient treatment delays, assuming the 
donor sample is considered suitable.  Indeed, when rigorous screening protocols are applied 
only a small percentage of would-be donors are ultimately selected – 10% in one study.9  
Hence the introduction of standardised stool banks modelled on the universal donor model, to 
help overcome limitations related to donor selection and screening logistics. At present in the 
Republic of Ireland there is no nationally agreed FMT policy or guidance should a hospital 
wish to set up a stool banking service, nor is there a national or regional stool banking 
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service. In a country such as ours (4.5 million population) with a low absolute number of 
patients with recurrent CDI,3 further evaluation is needed to explore the logistical challenges 
and costs associated with a national or regional  stool banking service.  Although national 
CDI surveillance collects data on recurrent CDI,3 there are no data on second or more 
recurrences, i.e. those for whom FMT is recommended. A full economic assessment would 
therefore be required to examine the option of a national / regional service against availing of 
an established service from abroad. The universal donor model is already used in many U.S. 
centres, with frozen donations acquired from stool banking organisations such as 
OpenBiome. These preparations, which are non-inferior to freshly prepared samples with 
regard to rates of clinical resolution, can be stored and available for use as needed.10 This 
approach is a worthy consideration where a national stool banking service is not in operation.  
Although not explored in this survey, factors that should be taken into account at an 
institutional level when commencing an FMT service are the national regulatory frameworks 
that FMT falls under (i.e. as a drug or biological material), ethics of donor screening and long 
term safety of microbiome manipulation. In Europe, the regulation of FMT is currently at the 
discretion of individual EU member states. Currently in Ireland no such national regulation 
exists. The United States Food and Drug Agency (FDA) views FMT as an investigational 
new drug (IND) meaning that the drug is normally made available through a clinical trial. Up 
to recently they have exercised enforcement discretion in this regard, however recent 
guidance suggests this is to change, particularly in situations where the FMT recipient does 
not know the donor (e.g. where the sample has been obtained from a stool bank). Where stool 
bank donation samples are to be used IND regulations are to be adhered to. This change in 
enforcement discretion may impact service provision, particularly in centres where samples 
for donation are routinely obtained from stool banking services. It does however ensure 
ongoing compliance with best practice in the relation to the obtaining of specimens and 
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screening of donors. It remains to be seen if future planned EU regulation of FMT donor 
material will hinder its widespread use. This may depend on whether it is regulated as a drug 
or bodily tissue. In the United Kingdom, the Medicines and Healthcare Products Regulatory 
Agency (MHRA) recently classified FMT as a medicinal product, not tissue, thus regulation 
of FMT changed from the Human Tissue Authority (HTA) to the MHRA. For any trial 
utilising FMT, MHRA approval should be sought. Again, this may impact on service 
provision and also the development of future research. Institutions need to ensure they are 
working within their national and EU frameworks and regulations. Where national 
regulations are absent, comparisons should be made to international standards to ensure the 
highest level of safety. This survey did not explore issues regarding protocols / regulations 
being followed in individual institutions. It is clear however that improved clarity at a 
national / European level is required. 
Planning a local FMT service should involve multidisciplinary input (e.g. laboratory, 
pharmacy and endoscopy services) and must consider legislative requirements.  It is not 
always possible for national protocols to take into account local nuances such as resources 
and administration processes.  Therefore locally agreed protocols, based around available 
national guidance, which considers these local variations will be crucial in determining 
success of the service.  
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Table I: Clostridium difficile infection (CDI) Management Practices of 94 Irish Clinicians 
Agents recommended for CDI 
treatment (by CDI episode) 
 
 
 
First episode 
-non-severe. 
[n (%)] 
First 
recurrence-
non-severe 
[n (%)] 
Second 
recurrence- 
non-severe 
[n (%)] 
Third / 
subsequent 
recurrence  
- non-severe 
[n (%)] 
Severe 
CDI 
[n (%)] 
Oral metronidazole 92 (97.9) 36 (38.3) 12 (12.8) 3  (3.2) 19 (20.2) 
Intravenous metronidazole 2 (2.1) 8 (8.5) 7 (7.4) 4 (4.3) 48 (51.1) 
Oral vancomycin 5 (5.3) 58 (61.7) 55 (58.5) 38 (40.4) 84 (89.4) 
Oral fidaxomicin 10 (10.6) 22 (23.4) 34 (36.2) 41 (43.6) 15 (16.0) 
Probiotics 15 (16.0) 12 (12.8) 14 (14.9) 13 (13.8) 9 (9.6) 
Faecal microbiota 
transplantation 
0 (0) 4 (4.3) 8 (8.5) 29 (30.9) 12 (12.8) 
Colectomy 0 (0) 2 (2.1) 0 (0) 0 (0) 22 (23.4) 
Intravenous immunoglobulin 0 (0) 1 (1.1) 1 (1.1) 6 (6.4) 22 (23.4) 
Rifaximin 
 
0 (0) 0 (0) 5 (5.3) 12 (12.8) 2 (2.1) 
Respondents who would have 
recommended / performed 
FMT in the past year if 
readily available (by CDI 
episode) 
0 (0) 7 (7.4) 20 (21.3) 41 (43.6) 22 (23.4) 
 
 
